<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="block">
            <roleset id="block.01" name="" wordnet="3">
                <roles>
                    <role n="0" descr="causer agent&#x0A;" />
                    <role n="1" descr="theme (process or entity being stopped)&#x0A;" />
                </roles>
                <example src="PERMUTATE" no="0">
                    <text>3-slice site mutations would block of 2.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>Antibody release of GR by 14-3-3eta for the phosphopeptide Y553 was specific, as labelling was blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">release of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>Block myeloid colony formation in TBST (Tris-buffered saline, 0.05% Tween-20) block 5% of beef serum albumin (for antiphosphorosine blots) or skimmed milk and antibody polled.</text>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that formation of myeloid colonies was blocked by inhibition of the PU.1 function in humans CD34+ before this regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that pre-incubation of antibodies with the phosphopeptide blocked labelling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with the phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because alanine has been shown to be able to block the action of a postulated repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because of 2 was blocked by 3-slice site mutations (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because pre-incubation of antibodies with phosphopeptide is shown to have blocked labeling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as 3-slice site mutations has been shown to be able to block of 2 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation has been shown to be able to block myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that Alanine was able to block the action of a postulate repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that greater GR in 14-3-3eta was blocked by inhibition of translation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">greater GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation was able to block myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation can block myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that labelling is blocked by preincubation of antibody with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that myeloid colony formation was blocked by inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that step II was blocked by slice site mutations (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">slice site mutations</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as labelling was blocked by preincubation of antibody with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as mutations of the cutting site has been shown to be able to block step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">mutations of the cutting site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as invasion of merozoites in vitro is blocked by antibody to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibody to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as labelling is blocked by pre-incubation of antibodies with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as labelling is blocked by preincubation of antibodies with phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">preincubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as step II is blocked by Mutations at the site of 3 cuts (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as the action of a postulate repressor has been shown to be blocked by Alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since inhibition of translation is shown to block increasing GR by 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">increasing GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>It could block RNA polymerase during stretch in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% of beef serum albumin (for antiphosphorosine blockers) or skimmed milk and antibody polled.</text>
                    <arg n="1">RNA polymerase during stretch</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>It is able to block the action of a recommended repressor in TBST (tris buffer serum, 0.05% Tween-20) containing 5% bovine serum albumin (for antiphosphorycin spots) or skimmed and antibody-probed milk.</text>
                    <arg n="1">the action of a recommended repressor</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>It was able to block Memberans in TBST (tris buffer serum, 0.05% Tween-20) containing 5% bovine serum albumin (for antiphosphorycin stains) or skimmed milk and was submitted to enzyme-linked immunosorbent tests.</text>
                    <arg n="1">Memberans</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and Tagetin may block RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and alanine has been shown to block the action of a postulated repressor.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>PU.1 has been regulated very early during the commitment of multi-potential progenitors to myeloid lineages and pre-incubation of antibodies with phosphopeptide has blocked label.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">label</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and invasion of merozoites in vitro can be blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>PU.1 is updated by regulation early during the engagement of multi-potential progenitors with the myeloid lineages and labelling can be blocked by preincubation of antibody with phosphopeptide.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>PU.1 was regulated at the start of multipotential progenitor commitment for myeloid strains and inhibition of translation blocked greater GR in 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">greater GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>Proassmal inhibition cannot induce any synergistic effect on the increase of GR 14-3-3eta induced in response to glucocorticoid, and Tagetin cannot block RNA polymerase during stretching, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during stretching</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>Proassmal inhibition does not induce any synergistic effect on the increase of GR 14-3-3eta in response to glucocorticoids, and translation inhibition does not block the elevation of GR in 14-3-3eta, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>Proeasomal inhibition cannot induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation is not able to block myeloid colony formation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and it is believed that the action of a postulate repressor is not blocked by Alanine, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and myeloid colony formation cannot be blocked by inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>Proteasomal inhibition cannot induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and 3-slice site mutations is not able to block of 2, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">3-slice site mutations</arg>
                    <arg n="1">of 2</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>Proteasomal inhibition cannot induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and pre-incubation of antibodies with phosphopeptide is not able to block taging, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>Proteasomal inhibition did not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and inhibition of UP.1 functions on CD34+ human progenitors before this regulation did not blocked formation of myeloid colonies, indicating that 14-3-3eta induced GR stabilization.</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>Proteasomal inhibition did not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and pre-incubation of antibodies with phosphopeptide did not blocked labelled, indicating that 14-3-3eta induced GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and taging is not able to be blocked by pre-incubation of antibodies with phosphopeptide, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>Step II is believed to be specifically blocked for alanine that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of the action of a postulate suppressor before recognition of the site of 3 cuts.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressor</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>Step II was specifically blocked for pre-incubation of antibody with phosphopeptide that do not affect the association of hPrps 16 and 17 to the sliceosome, indicating that these factors can work in a phase of labelling before the recognition of the site of the 3rd portion.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>Step II was specifically blocked for preincubation of antibody with phosphopeptide that do not affect the association of hPrps 16 and 17 to the sliceosome, indicating that these factors can work in a phase of taging before the recognition of the site of the 3rd portion.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>The RNA polymerase during elongation with antibodies for phosphopeptide Y553 is specific, since Tagetin may have blocked labelling.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>The antibody RNA polymerase during elongation for the phosphopeptide Y553 was specific, as Tagetin would block labeling.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>The antibody action of a prescribed repressoring in the Y553 phosphopeptide was specific, since alanine could have blocked label.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>The antibody increasing GR by 14-3-3eta for the phosphopeptide Y553 was specific, as inhibition of translation would have blocked labeling.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">increasing GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, since labelled can be blocked by pre-incubation of antibodies with phosphopeptide.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelled</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>The antibody labeling for the phosphopeptide Y553 was specific, since myeloid colony formation can be blocked by inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>The antibody myeloid colony formation for the phosphopeptide Y553 was specific, since labeling was blocked by inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>The antibody relevation of GR by 14-3-3eta for the phosphopeptide Y553 was specific, as translation inhibition was able to block labeling.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>The antibody step II for the phosphopeptide Y553 was specific, since labeling was able to be blocked by Mutations at the site of 3 cuts.</text>
                    <arg n="0">Mutations at the site of 3 cuts</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>The antibody the elevation of GR in 14-3-3eta for the phosphopeptide Y553 was specific, as translation inhibition could block labeling.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>The formation of myeloid colonies with antibodies for phosphopeptide Y553 is specific, since inhibition of UP.1 functions on CD34+ human progenitors before this regulation may have blocked labelling.</text>
                    <arg n="0">inhibition of UP.1 functions on CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>The increasing GR by 14-3-3eta with antibodies against the phosphopeptide Y553 is specific, since labelling is capable of being blocked by inhibition of translation.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">increasing GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>The labeling with antibodies for phosphopeptide Y553 is specific, since pre-incubation of antibody with phosphopeptide will block labelling.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>The labelling with antibodies to phosphopeptide Y553 is specific, since preincubation of antibody with phosphopeptide is able to block labelling.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>The rain of GR by 14-3-3eta with antibodies against phosphopeptide Y553 is specific, since labelling can be blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>The rain of GR by 14-3-3eta with antibodies for phosphopeptide Y553 is specific, since translation inhibition may have blocked labelling.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>The the action of a prescribed repressorling of antibodies in the Y553 phosphopeptide is specific, since alanine is able to block label.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>The the elevation of GR in 14-3-3eta with antibodies against phosphopeptide Y553 is specific, since labelling can be blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>UP. 1 is activated early during the multi-potential negotiation of progenitors for myeloid lineages and rain of GR by 14-3-3eta is thought to be blocked by translation inhibition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>alanine is more specific to distinguish between different RNA polymerases because it can blocks the action of a postulate suppressant (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>alanine is more specific to distinguish between different RNA polymerases because the action of a postulate repressor is blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate repressor</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>alanine that are able to specifically block the action of a prescribed repressor does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>alanine that can specifically block the action of a prescribed repressor does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before recognition of the 3-cut site.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a prescribed repressor</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>antibodies to RAP1 has blocked invasive merozoites in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasive merozoites in vitro</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>antibodies to RAP1 is able to block invasion of merozoite in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">invasion of merozoite in vitro</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation is more specific to distinguish between different RNA polymerases because myeloid colony formation was blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of PU. 1 function in CD34+ human progenitors prior to this Regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>inhibition of the PU.1 function in humans CD34+ before this regulation is more specific to distinguish between different RNA polymerases because it is able to block formation of myeloid colonies (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of the PU.1 function in humans CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>inhibition of the PU.1 function on human progenitors CD34+ before this regulation that are able to specifically block formation of myeloid colonies does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">inhibition of the PU.1 function on human progenitors CD34+ before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>inhibition of translation will block greater GR in 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">greater GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>label was blocked by pre-incubation of antibodies with phosphopeptide.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">label</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>mutations of the cutting site is more specific for the distinction between different RNA polymerases, since step II is blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">mutations of the cutting site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>mutations to the site of the 3rd portion is thought to block step II.</text>
                    <arg n="0">mutations to the site of the 3rd portion</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>pre-incubation of antibodies with phosphopeptide is more specific for the distinction between different RNA polymerases, as it can blocks labeling (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>pre-incubation of antibodies with phosphopeptide is more specific for the distinction between different RNA polymerases, because it blocked labeling (Mathews and Durbin, 1994), i.e., the action is independent of different initial factors.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>pre-incubation of antibodies with phosphopeptide is more specific for the distinction between different RNA polymerases, because it blocked labelling (Mathews and Durbin, 1994), i.e., the action is independent of different initial factors.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>pre-incubation of antibodies with phosphopeptide is more specific to distinguish between different RNA polymerases because labeling is blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>pre-incubation of antibodies with phosphopeptide that can specifically block labeling does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3 slice site.</text>
                    <arg n="0">pre-incubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>pre-incubation of antibody with phosphopeptide may have blocked labeling.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>pre-incubation of antibody with phosphopeptide will block labeling.</text>
                    <arg n="0">pre-incubation of antibody with phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>preincubation of antibodies with phosphopeptide that specifically blocked labelling does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the cutting site.</text>
                    <arg n="0">preincubation of antibodies with phosphopeptide</arg>
                    <arg n="1">labelling</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>preincubation of antibody with phosphopeptide has blocked taging.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>preincubation of antibody with phosphopeptide was believed to block taging.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>preincubation of antibody with phosphopeptide would block taging.</text>
                    <arg n="0">preincubation of antibody with phosphopeptide</arg>
                    <arg n="1">taging</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>the action of a postulate suppressant can be blocked by alanine.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressant</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>the action of a postulate suppressor can be blocked by alanine.</text>
                    <arg n="0">alanine</arg>
                    <arg n="1">the action of a postulate suppressor</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>translation inhibition blocked relevation of GR by 14-3-3eta.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>translation inhibition is more specific for the distinction between different RNA polymerases, as it can blocks the elevation of GR in 14-3-3eta (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>translation inhibition is more specific to distinguish between different RNA polymerases because relevance of GR by 14-3-3eta can be blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevance of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>translation inhibition is thought to have no effect on the association of hPrps 16 and 17 with sclerosis, block that these factors may work at a phase of relevance of GR by 14-3-3eta before the 3-slice site recognition.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">relevance of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>translation inhibition that are able to specifically block rain of GR by 14-3-3eta does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before recognition of the 3-cut site.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">rain of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>translation inhibition was believed to block the elevation of GR in 14-3-3eta.</text>
                    <arg n="0">translation inhibition</arg>
                    <arg n="1">the elevation of GR in 14-3-3eta</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>Antibody tagging for the phosphopeptide Y553 was specific, because myeloid colony formation is believed to be blocked by inhibition of PU.1 function in CD34+ human progenitors prior to this regulation.</text>
                    <arg n="0">inhibition of PU.1 function in CD34+ human progenitors prior to this regulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>Both RAP1 and 2 are important candidates for the vaccine because it has been shown that step II could be blocked by Mutations at the site of 3 splice (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the site of 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because aggregation AChR induced by agrone and phosphorylation was blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agrone and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because it has been shown that sporin can block AChR and arrhine-induced phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because staurosporin is shown to have blocked agrinin-induced AChR grouping and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrinin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>Both RAP1 and 2 are important candidates in the vaccine because the degradation of GR and the induction of a GR lift was blocked by a positive regulator in the glucocorticoid signal pathway (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and the induction of a GR lift</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that agrenin-induced AChR grouping and phosphorylation will be blocked by staurosporin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrenin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that degradation of GR and induction of GR elevation was blocked by positive regulation in the signaling pathway of glucocorticoids (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as it has been shown that step II has been blocked by Mutations in the 3 splice site (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations in the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>Both RAP1 and RAP2 are important candidates for the vaccine, as staurosporin has been shown to be able to block agrine-induced AChR and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as degradation of GR and induction of GR elevation has been shown to have been blocked by positive regulation in the signaling pathway of glucocorticoids (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as sporin are blocked aggregation and phosphorylation AChR induced in agro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">aggregation and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, as staurosporin are demonstrated to block agrenin-induced AChR grouping and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrenin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>Both RAP1 and RAP2 are important candidates for vaccination, since staurosporin has been shown to blocked aggregation AChR induced by agronin and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agronin and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>Mutations at site 3 splice could block step II.</text>
                    <arg n="0">Mutations at site 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>Mutations in cut-off site 3 that are believed to specifically block step II does not affect the association of hPrps 16 and 17 with sclerosis, indicating that these factors can work in a step of step II before recognition of the 3 slice site.</text>
                    <arg n="0">Mutations in cut-off site 3</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>PU. 1 is updated by early regulation during the involvement of multipotent progenitors with myeloid lines and staurosporin has been shown to block agrona-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrona-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>Proeasomal inhibition does not induce any synergic effect on the increase of GR induced by 14-3-3eta in response to glucocorticoids, and agrine-induced AChR and phosphorylation cannot be blocked by staurosporin, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>Proeasomal inhibition will not induce any synergic effect on the increase of GR 14-3-3eta in response to glucocorticoid, and staurosporin will not block agrinin-induced AChR grouping and phosphorylation, indicating that 14-3-3eta induces GR stabilization.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrinin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>Step II can be specifically blocked by sporin that do not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of AChR and arrhine-induced phosphorylation before the recognition of the 3-slice site.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>Step II is believed to be specifically blocked for positive regulation in the signaling pathway of glucocorticoids that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of degradation of GR and induction of GR elevation before recognition of the site of 3 cuts.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>Step II is specifically blocked by inhibition of UP.1 on the CD34+ human progenitors before this regulation that do not affect the association of hPrps 16 and 17 with the ear, indicating that these factors can operate in a phase of formation of myeloid colonies before the recognition of site 3.</text>
                    <arg n="0">inhibition of UP.1 on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>Step II is specifically blocked for Mutations in cut-off site 3 that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of step II before recognition of the site of 3 cuts.</text>
                    <arg n="0">Mutations in cut-off site 3</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>Step II is specifically blocked for Mutations in the 3 splice site that do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors can function at a stage of step II before recognition of the site of 3 cuts.</text>
                    <arg n="0">Mutations in the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>The Mutations in the 3 splice site that is able to specifically block step II does not affect the association of hPrps 16 and 17 with the sliceosome, indicating that these factors can work in a phase of step II before the recognition of the 3-cut site.</text>
                    <arg n="0">Mutations in the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>The antibody GR degradation and induction of GR elevation in the Y553 phosphopeptide is specific, since positive regulation in the signaling pathway of glucocorticoids blocked labeling.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">GR degradation and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>The antibody agrine-induced AChR and phosphorylation for the phosphopeptide Y553 was specific, as sporin would have blocked labeling.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>The antibody agrine-induced AChR and phosphorylation for the phosphopeptide Y553 was specific, as staurosporin could have blocked labeling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>The antibody agronin-induced AChR grouping and phosphorylation for the phosphopeptide Y553 was specific, as staurosporin may have blocked labeling.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agronin-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>The antibody argon-induced AChR grouping and phosphorylation in the Y553 phosphopeptide was specific, since labeling can be blocked by staurosporin.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>The antibody argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997)ing in the Y553 phosphopeptide was specific, as staurosporin was able to block label.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation is believed to be blocked by A0 (staurosporin) without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997)</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>The antibody formation of myeloid coloniesing in the Y553 phosphopeptide was specific, as inhibition of UP.1 on the CD34+ human progenitors before this regulation could block label.</text>
                    <arg n="0">inhibition of UP.1 on the CD34+ human progenitors before this regulation</arg>
                    <arg n="1">formation of myeloid colonies</arg>
                </example>
                <example src="REPLACE" no="33">
                    <text>The antibody labeling in the Y553 phosphopeptide was specific, as staurosporin would block agrine-induced AChR and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">agrine-induced AChR and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="34">
                    <text>The antibody the degradation of GR and induced a GR elevation for the phosphopeptide Y553 was specific, as a positive regulator in the glucocorticoid signal pathway could block labeling.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induced a GR elevation</arg>
                </example>
                <example src="REPLACE" no="35">
                    <text>The antibody the degradation of GR and induced a GR elevation in the Y553 phosphopeptide was specific, since labeling can be blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induced a GR elevation</arg>
                </example>
                <example src="REPLACE" no="36">
                    <text>The antibody the degradation of GR and the induction of a GR lift for the phosphopeptide Y553 was specific, since labeling was able to be blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and the induction of a GR lift</arg>
                </example>
                <example src="REPLACE" no="37">
                    <text>The degradation of GR and induce elevation of GR with antibodies for phosphopeptide Y553 is specific, since positive regulation in the signaling pathway of glucocorticoids blocked labelling.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">degradation of GR and induce elevation of GR</arg>
                </example>
                <example src="REPLACE" no="38">
                    <text>The in vitro merozoite invasioning of antibodies in the Y553 phosphopeptide is specific, since antibodies to RAP1 will block label.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">in vitro merozoite invasion</arg>
                </example>
                <example src="REPLACE" no="39">
                    <text>a positive regulator in the glucocorticoid signal pathway is more specific for the distinction between different RNA polymerases, as it can blocks the degradation of GR and induce a GR elevation (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and induce a GR elevation</arg>
                </example>
                <example src="REPLACE" no="40">
                    <text>mutations at the 3rd splice site is more specific to distinguish between different RNA polymerases because step II is blocked by it (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">mutations at the 3rd splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="41">
                    <text>positive regulation in the signaling pathway of glucocorticoids is more specific to distinguish between different RNA polymerases because it is able to block GR degradation and induction of GR elevation (Mathews and Durbin, 1994), i.e., the action is independent of different initiation factors.</text>
                    <arg n="0">positive regulation in the signaling pathway of glucocorticoids</arg>
                    <arg n="1">GR degradation and induction of GR elevation</arg>
                </example>
                <example src="REPLACE" no="42">
                    <text>sporin is more specific for the distinction between different RNA polymerases, since aggregation and phosphorylation AChR induced in agro was blocked by it (Mathews and Durbin, 1994), i.e., its action is independent of different initial factors.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">aggregation and phosphorylation AChR induced in agro</arg>
                </example>
                <example src="REPLACE" no="43">
                    <text>sporin will block AChR and arrhine-induced phosphorylation.</text>
                    <arg n="0">sporin</arg>
                    <arg n="1">AChR and arrhine-induced phosphorylation</arg>
                </example>
                <example src="REPLACE" no="44">
                    <text>staurosporin can block aggregation AChR induced by agrone and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agrone and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="45">
                    <text>staurosporin may have blocked argon-induced AChR grouping and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">argon-induced AChR grouping and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="46">
                    <text>staurosporin would block aggregation AChR induced by agrone and phosphorylation.</text>
                    <arg n="0">staurosporin</arg>
                    <arg n="1">aggregation AChR induced by agrone and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="47">
                    <text>step II can be blocked by Mutations at the site of 3 splice.</text>
                    <arg n="0">Mutations at the site of 3 splice</arg>
                    <arg n="1">step II</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
